郑之琬，男，医学博士，2020年进入金沙2004路线js5从事博士后工作。主要研究方向为杜氏利什曼原虫胞内增殖调控机制、耐药机制以及黑热病新型药物靶点的筛选工作。在杜氏利什曼原虫基因组、蛋白组、多组学联用、基因编辑、细胞和动物模型构建等方面具有扎实的科研基础和工作积累。主持金沙2004路线js5专职博士后研发基金和金沙2004路线js5博士后基金各1项。相关的研究成果以第一作者或通讯作者在Front Immunol、Parasit Vectors、Animals、Acta Parasitologica等国际主流学术刊物上发表。

主讲课程：人体寄生虫学、病原生物学实验Ⅰ、病原生物学实验实验Ⅱ。

荣获基础医学与法金沙2004路线js52022年第二届青年教师教学竞赛一等奖。

项目：

1. 金沙2004路线js5专职博士后研发基金，2022SCU12027，2022.1.1-2023.12.31，15万元，在研，主持。

文章：

1. Jianhui Zhang, Jiao Li, Kaifeng Hu, Qi Zhou, Xiaoxiao Chen, Jinlei He, Shuangshuang Yin, Yangjian Chi, Xuechun Liao, Yuying Xiao, Hanxiao Qin, Zhiwan Zheng, Jianping Chen. Screening Novel Vaccine Candidates for Leishmania Donovani by Combining Differential Proteomics and Immunoinformatics Analysis, Frontiers in Immunology, 2022, 13: 902066.（共同通讯）

2. Zhiwan Zheng, Jinlei He, Tao Luo, Jianhui Zhang, Qi Zhou, Shuangshuang Yin, Dali Chen, Jie Luo, Jianping Chen, Jiao Li. Mutation Characteristics and Phylogenetic Analysis of Five Leishmania Clinical Isolates, animals, 2022, 12(3): 321.

3. Zhiwan Zheng, Jianping Chen, Guangxu Ma, Abhay R Satoskar; Jiao L. Integrative genomic, proteomic and phenotypic studies of Leishmania donovani strains revealed genetic features associated with virulence and antimony-resistance, Parasites & Vectors, 2020, 13(1): 510.

4. Zhiwan Zheng, Jiao Li, Han Chen, Jinlei He, Qiwei Chen, Jianhui Zhang, Qi Zhou, DaliChen, Jianping Chen. Evaluation of in vitro antileishmanial efficacy of cyclosporin A and its non-immunosuppressive derivative, dihydrocyclosporin A, Parasites & Vectors, 2020, 13(1):94.

5. Jiao Li, Zhiwan Zheng, Gayathri Natarajan, Qiwei Chen, Dali Chen, Jianping Chen. The first successful report of the in vitro life cycle of Chinese Leishmania: the in vitro conversion of Leishmania amastigotes has been raised to 94% by testing 216 culture medium compound, Acta Parasitologica, 2017, 62(1): 154-163.（共一）